RCEL News & Events

Avita Medical announced that its board of directors has appointed Cary Vance as president and CEO, effective immediately. The board of directors has also appointed Jan Stern Reed as its chair, effective immediately. Vance, who has served as interim CEO since October 2025, will continue to serve on the board as an executive member. Vance has served on the Avita Medical board of directors since 2023 and was previously appointed chairman in 2025.

Avita Medical announced that Recell Go, its next-generation system for preparing Recell Spray-On Skin, has received certification from Australia's Therapeutic Goods Administration and has been listed on New Zealand's Web Assisted Notification of Devices database by Medsafe, enabling commercialization in both markets for burn and acute wound treatment. "The TGA certification and WAND listing of RECELL GO represents an important step in expanding access to RECELL," said Cary Vance, interim CEO of Avita Medical. "With RECELL GO, we are bringing greater standardization and efficiency to the preparation process, and together with our partner Revolution Surgical, we look forward to supporting adoption across Australia and New Zealand."

Avita Medical announced interim results from its Cohealyx-I multi-center study demonstrating a reduction of nearly 20 days in mean time to skin grafting for patients with full-thickness wounds. The results demonstrated statistical superiority versus a literature-derived benchmark, based on the lower bound of the 95% confidence interval. The benchmark was derived from a meta-analysis of published data on leading dermal matrices, representing approximately 900 patients. The interim analysis of 40 patients showed a median time to grafting of 11 days. Grafting was achieved as early as five days, with 25% grafted within seven days, and 72% grafted within 14 days. Investigators reported 90% satisfaction at the time of grafting, including among predominantly first-time users, supporting consistent performance and potential for broader adoption in clinical practice.

Avita Medical announced it has entered into a 10-year agreement with the Biomedical Advanced Research and Development Authority, or BARDA, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. The agreement, awarded under Project BioShield and valued at up to $25.5M, is intended to strengthen national preparedness for burn mass casualty incidents. Under the agreement, Avita Medical will: maintain an inventory of Recell products available for immediate deployment upon notice from BARDA and support surge procurement of additional product, ensuring scalable emergency response capacity and rovide logistics, quality assurance, and deployment readiness to meet BARDA's mission for preparedness.